Atai Beckley公布Emp-01(口服R-MDMA)二期a阶段追加结果:社交焦虑障碍改善显著且持续

美股速递
Apr 22

Atai Beckley公司近日发布了其候选药物Emp-01(口服R-MDMA)在二期a阶段临床试验中的进一步数据。结果显示,该药物在治疗社交焦虑障碍方面表现出显著且一致的改善效果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10